Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

CAUS vs. VPMCX: which is better?

Bottom line

CAUS vs VPMCX: the short answer

CAUS (Cloverpoint Core Alpha US ETF) and VPMCX (Vanguard PRIMECAP Fund) are both etfs.

Updated Nov 19, 2026

CAUS vs VPMCX side by side

CAUSVPMCX
TypeETFMutual fund
Fund familyARK InvestVanguard
CategoryLarge BlendLarge Blend
Expense ratio—0.35%
Annual cost per $10k—$35
10-yr cost on $10k (prospectus)—$443
Max front loadNone0%
12b-1 fee—0%
1-yr return—+29.9%
5-yr return (annualized)—+14.3%
10-yr return (annualized)—+15.2%
Best quarter—+17.3%
Worst quarter—−20.2%
Net assets (fund)—$96.1B
Number of holdings—173
Portfolio turnover—11%
Returns as of—Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

CAUS and VPMCX share none of their top holdings.

CAUS top 10

    VPMCX top 10

    1. Micron Technology Inc — 13.50%
    2. Intel Corp — 6.80%
    3. Eli Lilly & Co — 6.76%
    4. KLA Corp — 3.85%
    5. Alphabet Inc — 3.52%
    6. AstraZeneca PLC — 2.35%
    7. NVIDIA Corp — 2.33%
    8. Amazon.com Inc — 2.05%
    9. Tesla Inc — 1.89%
    10. Biogen Inc — 1.88%

    FAQ

    What is the difference between CAUS and VPMCX?
    CAUS (Cloverpoint Core Alpha US ETF) and VPMCX (Vanguard PRIMECAP Fund) are both etfs.
    Should I own both CAUS and VPMCX?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.